• Empire State Realty Trust, Inc. recently announced its third quarter 2025 operational results, including a rise in Manhattan office occupancy to 90.3%, the signing of 87,880 square feet of commercial leases, and the reaffirmation of 2025 earnings guidance with expected net income per share between US$0.22 and US$0.25.
• An important development was the new retail and culinary partnerships with Tourneau (Rolex) and SORA, signaling ongoing demand for ESRT’s prime retail spaces in high-traffic urban locations and highlighting the company’s ability to attract premium tenants.
• We'll explore how the combination of higher office occupancy and reaffirmed guidance impacts Empire State Realty Trust's investment outlook.

These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Empire State Realty Trust Investment Narrative Recap

To be a shareholder in Empire State Realty Trust, you need to believe that the demand for high-quality, centrally located office and retail space in Manhattan remains resilient, even as long-term industry headwinds continue. The recent rise in office occupancy and reaffirmed earnings guidance offer some support for the near-term outlook, but do not fundamentally alter the biggest catalysts, leasing momentum and tenant demand, or the principal risk of unattractive returns from high capital expenditures if revenue growth fails to keep pace.

Among recent updates, the signed lease with luxury retailer Tourneau (Rolex) illustrates ESRT’s continued ability to secure top-tier retail tenants. These types of partnerships are important: while high office occupancy helps, premium retail leasing underpins efforts to diversify revenue streams and could help mitigate the challenges of stagnant or slow office demand.

Yet, in contrast to the positive leasing headlines, investors should remain mindful of the impact rising operating expenses can have on ESRT's ability to ...

Empire State Realty Trust's outlook anticipates $797.6 million in revenue and $13.7 million in earnings by 2028. This implies a 1.5% annual revenue growth and a decrease in earnings of $26.7 million from the current $40.4 million.

Uncover how Empire State Realty Trust's forecasts yield a $8.97 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Ten individual fair value estimates from the Simply Wall St Community cluster at US$8.97 per share. While community consensus suggests one clear outlook, rising expenses remain top of mind for many and may weigh on future results. Explore why opinions differ and how this could affect your own view.

Explore another fair value estimate on Empire State Realty Trust - why the stock might be worth as much as 21% more than the current price!

Build Your Own Empire State Realty Trust Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Empire State Realty Trust research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Empire State Realty Trust research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Empire State Realty Trust's overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.